MYH9 and familial pancreatic carcinoma: Combined with previous in vitro results, we suggest that GALNT5 confers chemotherapy resistance to FOLFIRINOX in pancreatic cancer cells by binding to MYH9 and inhibiting NOTCH signaling in vivo.